Namilumab  (Synonyms: AMG-203; Anti-Human CSF2 Recombinant Antibody)

Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

CSF2/GM-CSF

Namilumab can be used for the research of rheumatoid arthritis with good tolerance^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1437  [NCBI]

P04141

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.78 kDa

1206681-39-1

Liquid

Colorless to light yellow

[Namilumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Namilumab (HY-P99307) neutralizes Recombinant Human GM-CSF (HY-P7016A) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.1991μg/mL in the presence of 0.5 ng/mL Recombinant Human GM-CSF.

• [1]. Huizinga TWJ, et, al. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther. 2017 Mar 9;19(1):53.  [Content Brief]